Fresh enthusiasm for Cerecor sours as lead drug flops in PhII depression study, shares crater
A few weeks ago, investors embraced shares of Cerecor in the big surge that swept up Alkermes’ stock following its clinical success for an anti …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
